NO304638B1 - Orally applicable drug forms for the treatment of central dopamine deficiency states - Google Patents

Orally applicable drug forms for the treatment of central dopamine deficiency states

Info

Publication number
NO304638B1
NO304638B1 NO932159A NO932522A NO304638B1 NO 304638 B1 NO304638 B1 NO 304638B1 NO 932159 A NO932159 A NO 932159A NO 932522 A NO932522 A NO 932522A NO 304638 B1 NO304638 B1 NO 304638B1
Authority
NO
Norway
Prior art keywords
weight
pct
parts
treatment
dopamine deficiency
Prior art date
Application number
NO932159A
Other languages
Norwegian (no)
Other versions
NO932522D0 (en
NO932522L (en
Inventor
Udo Wenzel
G Nther Weber
J Rgen Metzner
Alfred Dorr
Sabine Freitag
Ther Frank-Ulrich Fl
Frank-Michael Albert
Margit Haase
Edith Leistner
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of NO932522D0 publication Critical patent/NO932522D0/en
Publication of NO932522L publication Critical patent/NO932522L/en
Publication of NO304638B1 publication Critical patent/NO304638B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PCT No. PCT/DE92/00043 Sec. 371 Date Nov. 24, 1993 Sec. 102(e) Date Nov. 24, 1993 PCT Filed Jan. 23, 1992 PCT Pub. No. WO92/12710 PCT Pub. Date Aug. 6, 1992.A drug formulation administrable by mouth for the treatment of central dopamine deficiency condition, said formulation comprising 100 to 250 parts by weight of levodopa, 10 to 25 parts by weight of carbidopa, a polymer mixture in an amount of 10 to 200% based on said drugs, said polymer mixture consisting of: 0 to 100 parts by weight of a completely saponified polyvinyl alcohol having 0 to 3% residual acetyl content, a mean molecular weight of 60,000 to 80,000 and a total surface area of 0.1 m2/g to 0.18 m2/g, and 0 to 100 parts weight of a partially saponified polyvinyl alcohol having 10 to 18% residual acetyl content, a mean molecular weight of 80,000, a total surface area of 0.5 m2/g to 0.69 m2/g, and a specific pore volume of 0.2 cm3/g to 0.36 cm3/g, and an effective amount of customary galenic adjuvants.
NO932159A 1991-01-23 1993-07-09 Orally applicable drug forms for the treatment of central dopamine deficiency states NO304638B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (en) 1991-01-23 1991-01-23 Orally administrable drug form for the treatment of central dopamine deficiency states
PCT/DE1992/000043 WO1992012710A1 (en) 1991-01-23 1992-01-23 Orally administerable drugs for the treatment of central dopamine deficiency conditions

Publications (3)

Publication Number Publication Date
NO932522D0 NO932522D0 (en) 1993-07-09
NO932522L NO932522L (en) 1993-07-09
NO304638B1 true NO304638B1 (en) 1999-01-25

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932159A NO304638B1 (en) 1991-01-23 1993-07-09 Orally applicable drug forms for the treatment of central dopamine deficiency states

Country Status (22)

Country Link
US (1) US5532274A (en)
EP (1) EP0568577B1 (en)
JP (1) JP3382940B2 (en)
AT (1) ATE147264T1 (en)
AU (1) AU658171B2 (en)
BG (1) BG61677B1 (en)
CA (1) CA2101164C (en)
CZ (1) CZ280847B6 (en)
DE (2) DE4101873C2 (en)
DK (1) DK0568577T3 (en)
EE (1) EE03016B1 (en)
ES (1) ES2098496T3 (en)
FI (1) FI101040B (en)
GR (1) GR3022993T3 (en)
LT (1) LT3659B (en)
LV (1) LV11103B (en)
NO (1) NO304638B1 (en)
RO (1) RO114737B1 (en)
RU (1) RU2114619C1 (en)
SK (1) SK278736B6 (en)
UA (1) UA27848C2 (en)
WO (1) WO1992012710A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (en) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Pharmaceutical composition
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
MXPA04002973A (en) * 2001-09-28 2005-06-20 Johnson & Johnson Modified release dosage forms.
US20040180086A1 (en) * 2002-10-11 2004-09-16 Zebunnissa Ramtoola Gastro-retentive levodopa delivery form
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN1845728B (en) * 2003-08-29 2013-06-19 转化医药公司 Pharmaceutical compositions and method of using levodopa and carbidopa
DE602004031134D1 (en) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE USE OF LEVODOPA AND CARBIDOPA
WO2006103417A1 (en) * 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of parkinson's disease
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
KR101569604B1 (en) 2007-12-28 2015-11-16 임팩스 라보라토리즈, 인코포레이티드 Controlled release formulations of levodopa and uses thereof
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (en) * 2011-07-15 2013-01-23 한미약품 주식회사 Capsule formulation comprising montelukast or a pharmaceutically acceptable salt thereof, and levocetirizine or a pharmaceutically acceptable salt thereof
ES2823000T3 (en) 2013-10-07 2021-05-05 Impax Laboratories Llc Muco-adhesive controlled release formulations of levodopa and / or levodopa esters and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP7066351B2 (en) * 2017-08-18 2022-05-13 大原薬品工業株式会社 Levodopa-containing miniaturized tablets with good sustained release
JP6695013B1 (en) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 Binder
US20210395507A1 (en) * 2018-11-13 2021-12-23 Japan Vam & Poval Co., Ltd. Binder
EP3881838A4 (en) * 2018-11-13 2022-08-17 Japan Vam & Poval Co., Ltd. Bonding agent
EP3881839A4 (en) * 2018-11-13 2022-08-24 Japan Vam & Poval Co., Ltd. Bonding agent
US20230148062A1 (en) * 2020-04-10 2023-05-11 Japan Vam & Poval Co., Ltd. Binder
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (en) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Carrier for drugs
DE748317C (en) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Process for the production of threads, films, tapes, hoses u. Like. From incompletely saponified polyvinyl alcohols
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (en) * 1968-10-01 1976-05-17 Merck & Co Inc PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS AND THE MOLDED PRODUCTS OBTAINED BY THEIR USE.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (en) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablet consisting of porous, fibrous carrier - and as water swellable binder polyvinyl alcohol, cellulose ether or alginate
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (en) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmaceutical preparation.
JPS5852219A (en) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd Remedy for parkinson's disease (perkinsonism)
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (en) * 1986-08-26 1989-12-11 Lejus Medical Ab A MULTIPLE-UNIT DOS COMPOSITION OF L-DOPA
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
DE3875716D1 (en) * 1987-12-31 1992-12-10 Asta Medica Ag SYNERGISTIC COMBINATION OF DECARBOXYLASE INHIBITORS AND L-DOPA PELLETS.
DE3841955A1 (en) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistic combination of decarboxylase inhibitors and L-dopa pellets

Also Published As

Publication number Publication date
NO932522D0 (en) 1993-07-09
CA2101164C (en) 2001-04-24
SK369292A3 (en) 1998-02-04
NO932522L (en) 1993-07-09
FI933304A0 (en) 1993-07-22
DK0568577T3 (en) 1997-06-30
EP0568577A1 (en) 1993-11-10
ATE147264T1 (en) 1997-01-15
LV11103B (en) 1996-06-20
AU1186892A (en) 1992-08-27
LV11103A (en) 1996-04-20
EE03016B1 (en) 1997-08-15
UA27848C2 (en) 2000-10-16
US5532274A (en) 1996-07-02
EP0568577B1 (en) 1997-01-08
SK278736B6 (en) 1998-02-04
GR3022993T3 (en) 1997-07-30
AU658171B2 (en) 1995-04-06
LT3659B (en) 1996-01-25
DE4101873A1 (en) 1992-07-30
DE59207852D1 (en) 1997-02-20
LTIP555A (en) 1994-11-25
FI933304A (en) 1993-07-22
JPH06504543A (en) 1994-05-26
RO114737B1 (en) 1999-07-30
BG97894A (en) 1994-04-29
FI101040B (en) 1998-04-15
JP3382940B2 (en) 2003-03-04
CZ280847B6 (en) 1996-04-17
DE4101873C2 (en) 1993-12-09
WO1992012710A1 (en) 1992-08-06
BG61677B1 (en) 1998-03-31
ES2098496T3 (en) 1997-05-01
CZ369292A3 (en) 1993-09-15
CA2101164A1 (en) 1992-07-24
RU2114619C1 (en) 1998-07-10

Similar Documents

Publication Publication Date Title
NO304638B1 (en) Orally applicable drug forms for the treatment of central dopamine deficiency states
KR960700054A (en) APPLICATION OF RILUZOLE IN THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES
IL117356A0 (en) Controlled release pharmaceutical composition for oral administration
KR880000098A (en) Chondroitin Sulfate Immunostimulatory Composition
TW273550B (en)
KR920702216A (en) Use of Acetyl D-Carnitine in Glaucoma Treatment
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
RU93051537A (en) ORAL DOSAGE FORM
CA2136404A1 (en) Mucoadhesive, therapeutic or hygienic solid composition for application on oral or nasal mucosa
DE60116662D1 (en) INHIBITION OF SYSTEMIC INFECTIONS IN PEOPLE AND SWIVELING WITH BALLASTS
DE59410151D1 (en) Oral dosage forms containing flupirtine with controlled release of active ingredients
FI955837A0 (en) Process for the preparation of an orally administrable solid dosage form containing diclofenac
US5082665A (en) Anti-snoring formulations using yohimbine
KR920021144A (en) Uses of nizatidine to treat reflux esophagitis
ES2139774T3 (en) USE OF A COMBINATION OF ANTINEOPLASTS IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NEUROFIBROMATOSIS.
Farina et al. Antibacterial activity of Nicaraguan vegetal extracts used in folk medicine
ES2093515T3 (en) RILUZOL APPLICATION AS A RADIO-RESTORER.
KR960033451A (en) Hepatitis B Therapeutics Including Sodium Substituted Tryptophan
KR960021046A (en) Hepatitis B Therapeutics Containing Caffeic Acid
JPS57105423A (en) Chloroethylureidopropylpolysilsesquioxane
UA27711C2 (en) Pharmaceutical composition useful in the treatment of diseases in which leukotrienes are implicated

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees